In a recent study published in the journal Molecular Cancer, researchers unveiled a promising leada protein called IGF2BP1, which might serve as a crucial factor in fueling neuroblastoma's relentless advance, just like a spark igniting a wildfire. GMP production of 89Zr or 131I labeled antibodies.

IGF2BP1 plays a pivotal role in early life, facilitating rapid cell growth during embryonic development, a vital process for the formation of tissues and organs. However, beyond the embryonic stage, the sustained presence of IGF2BP1 often takes on a sinister role, promoting uncontrolled cell proliferation and assuming the role of a cancer catalyst.

The study's findings suggest that IGF2BP1 triggers the robust expression of another oncogenic protein, MYCN, a well-known oncogene frequently observed in neuroblastomas. This cascade of events allows the cell to evade apoptosis, the programmed cell death, and empowers it with the capability to perpetually replicate.

Dr. Sven Hagemann, one of the study's authors, underscores the potent oncogenic nature of both proteins, stating, "on a molecular level, both proteins are highly oncogenic, and IGF2BP1 drives this pro-cancer transformation by its very presence." In mouse experiments, all mice genetically induced to express IGF2BP1 ultimately developed neuroblastoma.

Theoretically, IGF2BP1 emerges as a promising therapeutic target. In healthy human cells, its expression diminishes significantly after infancy, whereas cancer cells persistently exhibit elevated levels. The research team is currently testing a molecular drug tailored to target IGF2BP1. Encouragingly, preclinical experiments have indicated minimal to no significant side effects associated with this treatment.

Dr. Hagemann added, "we've also discovered that IGF2BP1 plays a role in various other tumor types apart from neuroblastoma, so finding a molecule that targets IGF2BP1 could potentially revolutionize the treatment landscape for multiple cancer types."

While immune checkpoint inhibitors form the backbone of several immunotherapies, they are ineffective against cold tumors. The latest study comes from the Brigham and Women's Hospital and focuses on a protein called serine protease inhibitor B9 (SerpinB9, Sb9), whose potential significance in cancer cells has been underappreciated but which may pave the way for the development of novel immunotherapies.

How to construct bivalent scFv-linked F(ab')? BsAb

They used a number of animal models and found that inhibiting Sb9 with tiny compounds significantly decreased the development of tumors. This was accomplished by reducing the effectiveness of cold tumor defense systems and causing cell death within the tumors themselves. These findings were recently presented in an article titled "Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy".

According to Reza Abdi, MD, of the Division of Nephrology at Brigham and Women's Hospital, who was the paper's corresponding author, "In this work, we provide proof of concept utilizing a small molecule that is designed to destroy cancer via its own lytic enzyme mechanism. Immunotherapies, such as monoclonal antibodies or immune checkpoint inhibitors, are promising approaches that have garnered a substantial portion of research. On the other hand, antibodies are difficult to genetically manipulate and can potentially be harmful to patients. It's possible that developing smaller compounds that limit Sb9 activity will be easier, and that they'll also be more effective."

These researchers used the gene editing tool known as CRISPR-Cas9 to produce tumors in mice that lacked Sb9 and discovered that the growth of these tumors was slowed down significantly. Nevertheless, scientists also saw that Sb9 was expressed in cancer-associated fibroblasts as well as immunosuppressive cells that surrounded the tumors. This allowed the cancer to flourish by dampening the immune system's reaction to the disease, which in turn supported its development.

These researchers have known for a long time that Sb9, when present in normal immune cells, acts to protect these cells against their own damaging enzyme, which is termed granzyme B. (GrB). These cells produce an enzyme known as GrB, which is then released in order to combat invading cells. On the other hand, the fact that cancer cells include Sb9 and GrB is not commonly understood. The researchers discovered a high expression of Sb9 in a variety of human and animal malignancies. This protein makes it possible for tumors to withstand an onslaught by GrB.

Abdi stated, "The initial findings suggested that tumors missing the Sb9 protein developed more slowly. On the other hand, when we implanted knockdown Sb9 tumors in mice that lacked Sb9, we noticed a more dramatic reduction in the growth of the tumor. Based on these findings, it appears that if we are successful in locating a drug that can systematically inhibit this protein in both tumors and host cells, then we will be able to simultaneously target the various pathogenic weapons that are involved in the formation of tumors. These weapons include cancer-associated fibroblasts and immunosuppressive cells. This will allow us to achieve synergistic effects."

These researchers came up with a unique small-molecule inhibitor that binds to Sb9 and stops the protein from performing its function in mice. Particularly noteworthy is the fact that this small molecule inhibitor successfully controlled a number of solid tumor mouse models.

Abdi recognizes that much more study is needed to enhance the binding kinetics of this small molecule inhibitor of Sb9 and to establish the molecular basis of this interaction, as well as that thorough toxicity testing must be conducted before the drug can enter clinical trials.

Thats rightnon-human primates (NHPs) have become essential to cutting-edge biomedical research, especially in neurology, immunology, and vaccine development. With cerebrospinal fluid (CSF) from rhesus monkeys commanding up to $50,000 per vial and a limited global supply, primate biospecimens are now seen as biotechs version of liquid gold.

Why NHPs? The Genetic Edge
What makes NHPs so valuable in drug development? It all comes down to genetic similarity. Rhesus macaques, cynomolgus monkeys, and African green monkeys share upwards of 93% of their genome with humans. This genetic closeness translates to highly predictive pharmacokinetic and pharmacodynamic dataespecially in the brain.

CSF, in particular, offers a direct window into central nervous system activity. Because it crosses the blood-brain barrier, CSF samples provide real-time insight into how experimental drugs behave once inside the brain. In fact, published studies report CSF flow rates in macaques at approximately 0.018 mL/min, making them ideal for studying neurological drug distribution.

How to isolate BMECs from cynomolgus monkeys under GMP

The Supply Chain Squeeze
Despite soaring demand, supply of NHP biospecimens remains painfully constrained. Breeding cycles for monkeys can stretch 57 years, and ethical regulations have tightened globally. Meanwhile, samples like CSF have extremely narrow viability windowsoften less than 48 hours between extraction and analysisrequiring precise cold-chain logistics and processing.

Adding to the pressure, CSF is a critical resource for validating treatments for Alzheimers, Parkinsons, multiple sclerosis, and glioblastoma. Researchers are racing to evaluate biomarkers such as tau proteins and alpha-synuclein, making high-quality NHP CSF a cornerstone for translational CNS research.

Monkey Fluids in the Spotlight
Among available NHP models, rhesus macaque CSF remains the top choice for Alzheimers-related drug development. These samples are often cryopreserved at -80C and validated for PCR and western blot applications. Their consistency and compatibility with standard assays make them a preferred matrix for preclinical screening.

But rhesus monkeys arent the only stars of the show. Cynomolgus CSF has gained traction in Parkinsons disease studies, thanks to its use in spontaneous PD-like models. Meanwhile, the African green monkey is emerging as a promising model for mRNA vaccine research, offering valuable immunological and toxicological insight.

Ethics, Welfare, and Innovation
With increased use comes increased scrutiny. Ethical sourcing of NHP samples is a major concern among scientists, institutions, and regulators. Thats why responsible providers are now implementing stress-reduction collection protocols, round-the-clock veterinary monitoring, and complete traceability systems for every sample.

Some are even turning to blockchain technology to log the full history of each vialfrom animal welfare data to transport recordsensuring transparency across the research pipeline.

Where Science Meets Speed
For researchers, time is everything. In therapeutic areas like Alzheimers and rare CNS disorders, every day counts. Institutions equipped with vertically integrated NHP sourcing, in-house cryopreservation, and rapid shipping networks are proving critical in helping researchers meet urgent project deadlines without compromising quality.

Whether its a large pharmaceutical company preparing for an IND filing or a university lab validating a novel CNS biomarker, access to reliable, ethically sourced NHP biospecimens is fast becoming the deciding factor in research timelines.

Final Thoughts
Non-human primates have quietly become the linchpin of translational medicine. As neuroscience and immunotherapy push into more complex territory, NHP biospecimensespecially cerebrospinal fluidare no longer just lab supplies; theyre strategic assets. With innovation accelerating and ethical sourcing advancing, the primate gold rush is only just beginning.